TY - JOUR AU - Ueda, Takashi AU - Takesue, Yoshio AU - Nakajima, Kazuhiko AU - Ichiki, Kaoru AU - Ishikawa, Kaori AU - Takai, Yoshiko AU - Yamada, Kumiko AU - Tsuchida, Toshie AU - Otani, Naruhito AU - Takahashi, Yoshiko AU - Ishihara, Mika AU - Takubo, Shingo AU - Ikeuchi, Hiroki AU - Uchino, Motoi AU - Kimura, Takeshi PY - 2020 DA - 2020/07/08 TI - Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days JO - BMC Pharmacology and Toxicology SP - 50 VL - 21 IS - 1 AB - A trough concentration (Cmin) ≥20 μg/mL of teicoplanin is recommended for the treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections. However, sufficient clinical evidence to support the efficacy of this target Cmin has not been obtained. Even though the recommended high Cmin of teicoplanin was associated with better clinical outcome, reaching the target concentration is challenging. SN - 2050-6511 UR - https://doi.org/10.1186/s40360-020-00424-3 DO - 10.1186/s40360-020-00424-3 ID - Ueda2020 ER -